There were no statistically significant differences in any of the clinical (i.e., platelets and albumin) or histological variables (i.e., liver fat, NASH prevalence, SAF ballooning and lobular inflammation) related to NAFLD severity between F0–1 subjects and F2–4 subjects, except for the degree of liver fibrosis. Here, ALB is linked to metabolic dysfunction-associated steatohepatitis.